In Silico Assessment of Efficacy and Safety of IKur Inhibitors in Chronic Atrial Fibrillation: Role of Kinetics and State-Dependence of Drug Binding. by Ellinwood, Nicholas et al.
UC Davis
UC Davis Previously Published Works
Title
In Silico Assessment of Efficacy and Safety of IKur Inhibitors in Chronic Atrial Fibrillation: 
Role of Kinetics and State-Dependence of Drug Binding.
Permalink
https://escholarship.org/uc/item/7025987j
Journal
Frontiers in pharmacology, 8(NOV)
ISSN
1663-9812
Authors
Ellinwood, Nicholas
Dobrev, Dobromir
Morotti, Stefano
et al.
Publication Date
2017
DOI
10.3389/fphar.2017.00799
 
Peer reviewed
eScholarship.org Powered by the California Digital Library
University of California
ORIGINAL RESEARCH
published: 07 November 2017
doi: 10.3389/fphar.2017.00799
Frontiers in Pharmacology | www.frontiersin.org 1 November 2017 | Volume 8 | Article 799
Edited by:
Domenico Tricarico,
Università degli studi di Bari Aldo
Moro, Italy
Reviewed by:
Adam Hill,
Victor Chang Cardiac Research
Institute, Australia
Clemens Möller,
Hochschule Albstadt-Sigmaringen,
Germany
*Correspondence:
Stefano Morotti
smorotti@gmail.com
Specialty section:
This article was submitted to
Pharmacology of Ion Channels and
Channelopathies,
a section of the journal
Frontiers in Pharmacology
Received: 07 August 2017
Accepted: 23 October 2017
Published: 07 November 2017
Citation:
Ellinwood N, Dobrev D, Morotti S and
Grandi E (2017) In Silico Assessment
of Efficacy and Safety of IKur Inhibitors
in Chronic Atrial Fibrillation: Role of
Kinetics and State-Dependence of
Drug Binding.
Front. Pharmacol. 8:799.
doi: 10.3389/fphar.2017.00799
In Silico Assessment of Efficacy and
Safety of IKur Inhibitors in Chronic
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Current pharmacological therapy against atrial fibrillation (AF), the most common cardiac
arrhythmia, is limited by moderate efficacy and adverse side effects including ventricular
proarrhythmia and organ toxicity. One way to circumvent the former is to target ion
channels that are predominantly expressed in atria vs. ventricles, such as KV1.5,
carrying the ultra-rapid delayed-rectifier K+ current (IKur). Recently, we used an in silico
strategy to define optimal KV1.5-targeting drug characteristics, including kinetics and
state-dependent binding, that maximize AF-selectivity in human atrial cardiomyocytes
in normal sinus rhythm (nSR). However, because of evidence for IKur being strongly
diminished in long-standing persistent (chronic) AF (cAF), the therapeutic potential of
drugs targeting IKur may be limited in cAF patients. Here, we sought to simulate the
efficacy (and safety) of IKur inhibitors in cAF conditions. To this end, we utilized sensitivity
analysis of our human atrial cardiomyocyte model to assess the importance of IKur for
atrial cardiomyocyte electrophysiological properties, simulated hundreds of theoretical
drugs to reveal those exhibiting anti-AF selectivity, and compared the results obtained
in cAF with those in nSR. We found that despite being downregulated, IKur contributes
more prominently to action potential (AP) and effective refractory period (ERP) duration in
cAF vs. nSR, with ideal drugs improving atrial electrophysiology (e.g., ERP prolongation)
more in cAF than in nSR. Notably, the trajectory of the AP during cAF is such that more
IKur is available during the more depolarized plateau potential. Furthermore, IKur block
in cAF has less cardiotoxic effects (e.g., AP duration not exceeding nSR values) and
can increase Ca2+ transient amplitude thereby enhancing atrial contractility. We propose
that in silico strategies such as that presented here should be combined with in vitro and
in vivo assays to validate model predictions and facilitate the ongoing search for novel
agents against AF.
Keywords: ultra-rapid delayed-rectifier K+ current, atrial fibrillation, mathematical modeling, ion channel blockers
Abbreviations: AP, action potential; APD, AP duration; APD40, APD to 40% repolarization; APD90, APD to 90%
repolarization; AF, atrial fibrillation; C, closed state; cAF, chronic AF; CaT, Ca2+ transient; CaTamp, CaT amplitude; CL, cycle
length; EAD, early afterdepolarization; Em, membrane potential; ERP, effective refractory period; GKur, maximal conductance
of the ultra-rapid delayed-rectifier K+ current; I, inactivated state; IKur, ultra-rapid delayed-rectifier K
+ current; nSR, normal
sinus rhythm; O, open state.
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INTRODUCTION
Atrial fibrillation (AF) is characterized by rapid, irregular heart
contractions following fast, disorganized electrical signals in the
atria. AF is the most common cardiac arrhythmia, occurring
in 1–2% of the general population and projected to increase
dramatically in the coming decades (to 4% by 2050) with an
aging westernized population (Andrade et al., 2014). The most
effective current treatment for preventing recurrence of AF in
the clinic is radiofrequency ablation. Pharmacological therapy
against AF is limited by low efficacy and substantial adverse
side effects including an increased risk of lethal ventricular
tachyarrhythmias.
To maximize efficacy and minimize proarrhythmic risk, an
AF-selective drug should exert potent effects on fibrillating atria
without significantly impacting ventricular tissue function during
normal sinus rhythm (nSR) (Ehrlich et al., 2008; Van Wagoner
et al., 2015). A potential strategy to achieve this goal is to
target ion channels that are predominantly expressed in atria
vs. ventricles, such as KV1.5, carrying the ultra-rapid delayed-
rectifier K+ current (IKur). Genetic mutations causing both loss-
and gain-of-function of IKur have been associated with atrial
arrhythmias in human (Olson et al., 2006; Christophersen et al.,
2013; Colman et al., 2017). In a previous investigation, we
used an in silico strategy to define optimal KV1.5-targeting drug
characteristics, including kinetics and state-dependent binding,
that maximize AF-selectivity (i.e., fast pacing-rate selectivity) in
human atrial cardiomyocytes (Ellinwood et al., 2017). Because
this work was conducted in atrial cardiomyocytes under nSR
conditions, the best-performing drug properties identified would
have relevance for patients with paroxysmal AF that have not
undergone extensive AF-related electrical remodeling (Grandi
et al., 2012; Nattel and Dobrev, 2016).
Building on our previously established simulation framework,
the major goal of this investigation was to determine the optimal
drug characteristics of IKur inhibitors in long-standing persistent
(chronic) AF (cAF) conditions. Although not a universal finding
(Yue et al., 1997; Bosch et al., 1999; Grammer et al., 2000;
Workman et al., 2001), previous reports showed that IKur is
strongly diminished in cAF patients (Van Wagoner et al., 1997;
Brandt et al., 2000; Van Wagoner and Nerbonne, 2000; Dobrev
and Ravens, 2003; Christ et al., 2008; Caballero et al., 2010),
making the therapeutic potential of inhibitors targeting this
current uncertain (Ravens et al., 2013; Grandi and Maleckar,
2016). Indeed, evidence of anti-arrhythmic efficacy of KV1.5
inhibitors in clinical trials is lacking (Ravens et al., 2013).
However, recent studies have suggested an anti-arrhythmic
potential of IKur-targeting drugs in cAF (Christ et al., 2008;
Ford et al., 2013, 2016; Loose et al., 2014), as they can prolong
action potential (AP) and effective refractory period (ERP) in
atrial cardiomyocytes of cAF patients. Moreover, experimental
evidence suggests that block of IKur enhances force of contraction
of isolated human atrial trabeculae in cAF (Wettwer et al.,
2004; Schotten et al., 2007). Our human atrial cardiomyocyte
model confirmed that block of IKur results in prolongation and
elevation of the AP plateau, which augments the Ca2+ transient
(CaT) amplitude (CaTamp), thereby eliciting a positive inotropic
effect (Grandi et al., 2011). Thus, IKur might be a useful atrial-
selective target to potentially prevent reentry and related atrial
hypocontractility in cAF. We propose that our computational
approach, combined with in vivo and in vitro validation, might
be useful to facilitate the identification of atrial-selective anti-
arrhythmic drugs against AF (Bers and Grandi, 2011; Grandi and
Maleckar, 2016).
METHODS
Atrial AP Model and Simulations
APs and CaTs were simulated with the Grandi et al. model of
the human atrial cardiomyocyte in nSR and cAF (Grandi et al.,
2011; Morotti et al., 2016b). IKur gating was described by a 6-state
Markov type model (Figure 1A) as in Ellinwood et al. (2017), and
IKur maximal conductance (GKur) in cAF was reduced by 50%
compared to nSR (Grandi et al., 2011).
Simulations were equilibrated for 300 beats at 1-Hz pacing
or 900 beats at 3-Hz pacing. After the 300th or 900th beat,
the time to 40 and 90% repolarization of the AP (APD40
and APD90) were calculated, along with diastolic intracellular
Ca2+ concentration ([Ca2+]i), CaTamp and time to 50% CaT
decay. The atrial ERP was determined using a standard S1-S2
premature stimulation protocol (Wang et al., 1996; Shinagawa
et al., 2000; Christ et al., 2008; Zhao et al., 2009), where the
S1 basal stimulus (5ms in duration) was applied to a steady-
state human atrial cardiomyocyte model. As previously described
(Ellinwood et al., 2017), ERP was determined by applying the
premature S2 stimulus (5ms in duration, 2-fold the diastolic
threshold of excitation) at progressively smaller S1-S2 intervals
from 700ms to refractoriness by decrements of 2ms. The longest
S1-S2 interval that failed to elicit an AP was taken as the local
ERP (i.e., maximum upstroke velocity ≥5 V/s and AP with an
amplitude ≥50% of the amplitude of the preceding AP elicited
by S1).
An irregular pacing protocol was run for 20 s, starting from
steady-state conditions at the fixed 3-Hz pacing. The cycle
length (CL) was allowed to vary randomly following a uniform
distribution between 285.7 and 400ms, corresponding to a
minimum pacing frequency of 2.5Hz and a maximum pacing
frequency of 3.5Hz, with amean of 333.3ms (corresponding to 3-
Hz pacing). The time course ofmembrane potential (Em), APD90,
and CL was tracked over the course of the simulation.
All simulations and analysis were performed in MATLAB
(The MathWorks, Natick, MA, USA) using the stiff ordinary
differential equation solver ode15s. The model code is available
for download at the following webpages: https://somapp.ucdmc.
ucdavis.edu/Pharmacology/bers/ and http://elegrandi.wixsite.
com/grandilab/downloads.
Parameter Sensitivity Analysis
Parameter sensitivity analysis was performed with the
population-based approach described in Sobie (2009), Morotti
et al. (2017), and Morotti and Grandi (2017) to investigate the
role of various currents and transporters in the regulation of AP
duration (APD), ERP, and CaT characteristics. Two populations
of 900 atrial cardiomyocyte models were generated by randomly
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FIGURE 1 | Sensitivity of nSR and cAF cardiomyocyte electrophysiology to
IKur changes. (A) Drug-free Markov model of IKur derived from Zhou et al.
(2012). The model has 4 closed states (C1, C2, C3, C4), a conducting open
state (O), and an inactivated state (I). Transition rates equations and
parameters are those in Ellinwood et al. (2017). (B) AP, CaT, and IKur in a
subset of 300 cAF cardiomyocyte model variants at 1-Hz and 3-Hz pacing
rates. (C) Bar graphs show the average regression coefficients indicating how
perturbations in GKur affect APD40, APD90, and ERP in nSR and cAF at 1-Hz
and 3-Hz pacing rates. Error bars represent one standard deviation.
varying the values of 18 parameters (see list in the Supplementary
Materials) in the baseline nSR and cAF models. Specifically, the
default value of each conductance or maximal transport rate
was independently varied with a log-normal distribution (with
standard deviation of 0.1). Multivariable regression (non-linear
iterative partial least squares method) on log-transformed values
was performed for 30 random subsets of 300 model variants
from the 900-variant population to correlate the variation in
each parameter to the consequent effect on each output. In
Figure 1C and Figures S1–S6 bars represent the mean regression
coefficients and error bars represent one standard deviation.
KV1.5 Drug-Binding Model
We utilized our recent IKur Markov formulation and approach
to describe various drug-KV1.5 channel binding schemes
(Figures 2A,F; Ellinwood et al., 2017), as done by Lee et al.
(2016). We previously showed that open state (O) blockers and
open and inactivated state (O & I) blockers that target KV1.5
display fast pacing-rate selectivity (Ellinwood et al., 2017). Thus,
we focused on these two types of inhibitors when examining the
relationship between electrophysiological parameters and drug-
binding kinetics in cAF. We considered different theoretical
drugs with variable forward (kon) and reverse (koff) drug-
binding rates to the open and inactivated states of the KV1.5
channel in the predicted physiological range of 0.01–100 s−1
(Lagrutta et al., 2006) using half-logarithmic increments resulting
in nine transition rates for each drug state transition (0.01, 0.03,
0.1, 0.3, 1, 3, 10, 30, 100 s−1). For a particular state of the
channel, dissociation constants (Kd) for our drug scenarios were
calculated as koff/kon, and affinity constants were calculated as
kon/koff. To investigate the effects of these drug characteristics, for
a given state-dependent binding inhibitor, we varied kon and koff
together (kon = koff) or considered all permutations of the nine
different rates of drug binding (producing a total of 81 different
drug scenarios). For drugs that could bind to multiple states of
the KV1.5 channel, we also varied the relative affinity to open
(KO) vs. inactivated state (KI). For O & I blockers, we included
transitions between drug-bound states (orange transitions in
Figure 2F) when specified. All drugs were simulated at the
concentration causing a 50% reduction in peak IKur (i.e., IC50).
IC50 values were computed as described previously (Ellinwood
et al., 2017), using a 200-ms down-ramp voltage-clamp protocol
from +30 to −60mV. After the application of a given [drug]
(range: 1 nM−1M), we allowed sufficient time for the degree
of block to reach equilibrium. IC50 values were calculated at 1-
and 3-Hz pacing rates as the [drug] causing a 50% reduction
in peak IKur compared to drug-free conditions. We chose the
down-ramp, as compared to a typical square pulse, because it
more closely resembles the relative state occupancies of the closed
states, open state, and inactivated state of the KV1.5 channel
during a physiological atrial AP, as we have shown in (Ellinwood
et al., 2017).
RESULTS
Role of IKur in nSR and cAF Atrial
Electrophysiology
We built 900 variations of our nSR and cAF human atrial
cardiomyocyte models (Grandi et al., 2011) at 1- and 3-
Hz pacing, and performed parameter sensitivity analysis on
30 random subsets of 300 model variants to determine how
alterations in each maximum ionic conductance/transport
rate differentially (in cAF vs. nSR) affect electrophysiological
properties including APD40, APD90, ERP, CaTamp, diastolic
[Ca2+]i, and time to 50% CaT decay (Figures S1–S6).
Simulated APs and CaTs in a representative group of 300 cAF
cardiomyocyte model variants are shown in Figure 1B, and
the average regression coefficients for GKur in nSR and cAF
conditions at 1- and 3-Hz pacing are in Figure 1C. The values
are negative because an increase in IKur shortens APD40, APD90,
and ERP on average according to the regression algorithm. The
analysis revealed that, while at a slow pacing rate APD90 and ERP
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FIGURE 2 | Effect of state-dependence and kinetics of drug binding on APD90. APD90 was determined for open (schematic in A, B, 1-Hz and D, 3-Hz pacing rate)
and open and inactivated (schematic in F, G 1-Hz and I, 3-Hz pacing rate) state blockers given nine different rates of binding kinetics between 0.01 and 100 s−1
using half-logarithmic increments, whereby koff = kon, Kd = 1µM. For O & I blockers, we either allowed or prevented transitions between drug-bound states (orange
vs. black traces in G,I). Simulations were also run in nSR and cAF drug-free conditions, and in cAF given a 50 and 100% reduction in GKur (dotted and dashed lines in
B,D,G,I). Simulations were equilibrated for 300 beats at 1-Hz pacing or 900 beats at 3-Hz pacing using a [drug] equal to the IC50 value. (C,E,H,J) show the closed,
open, inactivated and drug-bound (dB, i.e., Od or Od+Id) state occupancies during an AP for three different drug-binding kinetics (koff = kon = 0.01, 3, and 100 s
−1).
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aremore sensitive to changes in GKur, APD40 is similarly sensitive
in nSR and cAF (Figure 1C). At 3-Hz pacing, GKur impacts AP
and ERP prolongation more in cAF vs. nSR despite the fact that
GKur is smaller in cAF conditions. This points to IKur inhibition
as a promising approach to counteract the abbreviated APD and
ERP in cAF, while having a more moderate effect at physiological
pacing rates. Therefore, we next ran simulations to reveal IKur-
targeting drug properties that exhibit anti-AF selectivity and
efficacy along with minimized proarrhythmic risk in cAF.
Effect of Conformational State Specificity
and Binding/Unbinding Kinetics on Human
Atrial Cardiomyocyte APD at Normal and
Fast Pacing Rates in cAF Conditions
Figure 2 shows changes in APD caused by O and O& I inhibitors
at varying drug-binding kinetics, whereby kon is set equal to koff
(i.e., Kd = 1µM). These are compared to no block, 50, and
100% reduction in GKur in cAF conditions, as well as no block in
nSR conditions. Similar to our findings in nSR (Ellinwood et al.,
2017), both types of inhibitors display a biphasic relationship
between APD and drug-binding kinetics at 1- and 3-Hz pacing.
At 1-Hz pacing, APD in the presence of drug is comparable to
a 50% reduction in GKur at slow and fast drug-binding kinetics
(Figures 2B,G). Significant APD prolongation is only seen for
intermediate drug-binding kinetics (0.3–30 s−1 for the open state
blocker and 1–30 s−1 for the open and inactivated state blocker),
and goes well beyond the little APD prolongation resulting from
a constant 50% reduction in GKur. However, even the maximal
APD prolongation produced by an O or O & I inhibitor in cAF
is still ∼50ms less than the APD in nSR in drug-free conditions,
which we interpret to suggest that such drugs would have limited
toxicity at 1-Hz pacing rate.
At 3-Hz pacing, the two types of inhibitors cause stronger
relative prolongation as compared to 1-Hz pacing across the
same range of drug-binding kinetics (Figures 2D,I). Notably,
all simulated drugs caused APD prolongation at 3-Hz pacing,
but the maximal prolongation produced by these theoretical
inhibitors did not match the APD prolongation caused by a
100% reduction in GKur. However, drugs with intermediate drug-
binding kinetics (3–30 s−1 for the O blocker and 10–30 s−1 for
the O & I blocker) did extend the APD at 3-Hz pacing above
the APD in nSR conditions given no block of IKur. Thus, even
though GKur is reduced by 50% in cAF as compared to nSR,
Figure 2 illustrates that IKur inhibitors can still prolong APD in
cAF, particularly at 3-Hz pacing.
Figures 2C,H,E,J display the closed (red), open (blue),
inactivated (green), and drug-bound (gray) state occupancies
during the steady-state AP for the slowest (0.01 s−1),
intermediate (3 s−1), and fastest (100 s−1) drug-binding
rates. In general, for the slowest drug-binding kinetics, the
inhibitors do not bind readily during the AP, and the drug-bound
state stays level below 0.4. At intermediate drug-binding kinetics,
the inhibitors bind readily during the AP, thus significantly
shrinking the open state occupancy. In addition, the off-rate
of drug binding is slow enough to achieve maintenance in the
drug-bound state during the AP. This allows for considerable
AP prolongation, almost mimicking complete block of IKur.
Finally, for the fastest drug-binding kinetics, the drugs again
bind readily during the AP, but the off-rate of drug binding is
so fast as to cause cycling between the drug-free open state and
the drug-bound open state during a single AP. This results in
prolongation of the drug-free open state occupancy later in the
AP that limits AP prolongation. These results are consistent
with our previous simulations in nSR. However, given the more
positive plateau in the cAF cardiomyocyte AP, KV1.5 channels
stay open longer, and inactivate more markedly (especially at
3-Hz pacing) as compared to nSR (Figure S7).
Given not only the rapid, but irregular electrical activity seen
with AF, we sought to determine how the kinetics of drug binding
of IKur inhibitors affected the time course of Em (Figure 3B)
and APD90 (Figure 3C) in cAF cardiomyocytes with a randomly
variable CL (Figure 3A). Results in drug-free conditions and for
an O & I blocker (modeled as in Figure 2F, black) with kon
= koff (Kd = 1µM) in Figure 3 again demonstrate a biphasic
relationship between drug-binding kinetics and average APD90
(Figure 3D), as seen with constant pacing (Figure 2I). Thus, for
all future simulations, we used a constant pacing interval that can
more easily be standardized in a high-throughput drug-screening
process.
Effect of Conformational State Specificity
and Binding/Unbinding Kinetics on Human
Atrial Cardiomyocyte ERP at Normal and
Fast Pacing Rates in cAF Conditions
The desired effect of IKur inhibitors is prolongation of atrial
ERP (Amos et al., 1996; Christ et al., 2008; Sanchez et al.,
2012; Loose et al., 2014; Ford et al., 2016), particularly during
fast pacing rates typifying AF. Thus, we assessed the effects of
binding/unbinding kinetics on the ERP for O (Figures 4A,B)
and O & I (Figures 4C,D) blockers. Simulations reveal a similar
biphasic relationship between ERP and drug-binding kinetics at
1- and 3-Hz pacing for both types of inhibitors, which mirror the
drugs’ effects on APD (Figure 2).
At 1-Hz pacing, IKur inhibitors cause minimal ERP
prolongation at slow drug-binding rates (≤0.3 s−1 for O
blockers and ≤1 s−1 for O & I blockers) and fast drug-binding
rates (100 s−1). Although substantial ERP changes are predicted
at intermediate drug-binding rates (1–30 s−1 for O blockers
and 3–30 s−1 for O & I blockers), ERP prolongation remains
∼62ms lower than the ERP in nSR given no block of IKur for
both inhibitors.
At 3-Hz pacing, however, IKur inhibitors appear to be
more effective at extending ERP than APD, which is a
favorable drug property as previously demonstrated for Class
I antiarrhythmic drugs which cause clinically relevant post-
repolarization refractoriness. For all drug-binding kinetics, ERP
prolongation is at least equivalent to that caused by a constant
50% reduction in GKur (Figures 4B,D). Notably, for intermediate
drug-binding kinetics (3–30 s−1 for O inhibitors and 10–30 s−1
for O & I inhibitors), drug-induced ERP prolongation extends
above the ERP in nSR in drug-free conditions, and the fastest
drug-binding kinetics prolong the ERP to a point that closely
Frontiers in Pharmacology | www.frontiersin.org 5 November 2017 | Volume 8 | Article 799
Ellinwood et al. IKur Inhibitors in Chronic Atrial Fibrillation
FIGURE 3 | Effect of drug-binding kinetics on APD during irregular pacing. (A) Beat-to-beat changes in CL during a 20-s irregular pacing protocol and the resultant
time-course of (B) Em, and (C) APD90 are shown in cAF cardiomyocytes in drug-free conditions (black), and for O & I blockers with slow (0.01 s
−1, blue), intermediate
(10 s−1, red), and fast (100 s−1, green) drug-binding kinetics, given kon = koff . (D) summarizes the percent prolongation (mean APD90 after application of drug divided
by mean APD90 in drug-free conditions during the simulation) for nine different rates of binding kinetics between 0.01 and 100 s
−1 using half-logarithmic increments,
whereby kon = koff , Kd = 1µM. These results are compared to 50, and 100% reduction in GKur (dotted lines) given the same irregular pacing protocol in (A).
resembles that in nSR in drug-free conditions. These drugs
showing substantial ERP prolongation at 3-Hz pacing in cAF
(with APD at slow pacing rates being well below that in nSR, see
Figure 2) might represent suitable compounds for AF-selective
therapy.
Effects of Drug Binding/Unbinding Kinetics
with Variable Kd on APD, ERP, and Ca
2+
Handling
Figures 2, 3, 4 show the results from drug scenarios where the
on- and off-rate of drug binding are equal to one another (kon =
koff, Kd = 1µM), but even closely related IKur inhibitors can have
dissimilar Kd values (Lagrutta et al., 2006). Thus, we simulated
all permutations of the nine different rates of drug binding (0.01
to 100 s−1), yielding 81 different combinations of kon and koff
for the O & I state inhibitors (assuming equal affinities for open
and inactivated states) at 1- and 3-Hz pacing. We assessed the
effects of these drugs (at their IC50 concentration) on APD, ERP,
CaTamp, and diastolic [Ca
2+]i. Figure 5 shows the output of the
simulations for an O & I inhibitor (modeled as in Figure 2F,
black) in the form of a heatmap, where the diagonals of the
squares from the bottom left to the top right corner correspond
to drug scenarios where kon = koff (Kd = 1µM). Except for the
drugs with the largest Kd values (koff >> kon), when kon is held
constant, APD, ERP, and Ca2+ handling are not very sensitive
to changes in koff. Thus, the effects of IKur inhibitors on atrial
electrophysiology and Ca2+ handling are largely driven by kon
rates as compared to koff rates.
In cAF conditions, ideal IKur inhibitors exhibiting AF-
selectivity will prolong atrial refractoriness (ERP prolongation
at 3-Hz pacing), have limited toxicity (minimal to no APD
prolongation at 1-Hz pacing), and have a positive inotropic
effect (an increase in CaTamp at 1-Hz pacing). O & I inhibitors
with a large Kd do not display any of the desired favorable
drug properties including prolongation of ERP at 3-Hz pacing
(Figure 5B) or increase in CaTamp (Figures 5C,D), as their effects
on APD, ERP, and Ca2+ handling are minimal, resembling
drug-free conditions. Intermediate kon rates (3–30 s
−1 for 1-
Hz pacing and 10–30 s−1 for 3-Hz pacing) cause the most
significant increase in all the outputs displayed in Figure 5. For
example, drugs with a kon rate equal to 10 s
−1 cause the greatest
ERP prolongation at 3-Hz pacing (Figure 5B) and increase in
CaTamp and diastolic [Ca
2+]i (Figures 5C,E). Note, there is also
significant APD prolongation at 1-Hz pacing when kon is in
the intermediate drug-binding range (Figure 5A), but none of
the 81 permutations of the simulated open and inactivated state
inhibitor cause the APD to get close to the APD in nSR at 1-Hz
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FIGURE 4 | Effect of state-dependence and kinetics of drug binding on ERP. ERP was determined for open (A, 1-Hz and B, 3-Hz pacing rate) and open and
inactivated (C, 1-Hz and D, 3-Hz pacing rate) state blockers given nine different rates of binding kinetics between 0.01 and 100 s−1 using half-logarithmic increments,
whereby koff = kon, Kd = 1µM. For O & I blockers, we either allowed or prevented transitions between drug-bound states (orange vs. black traces in C,D).
Simulations were also run in nSR and cAF drug-free conditions, and in cAF given a 50 and 100% reduction in GKur.
pacing (320ms). Thus, the APD prolongation seen in Figure 5A
does not necessarily disqualify any of these theoretical drug
candidates for AF therapy. Likewise, at 3-Hz pacing, the increase
in CaTamp and diastolic [Ca
2+]i mirrors the prolongation in
APD and ERP at 3-Hz pacing (Figures 5D,F). While an excessive
increase in diastolic [Ca2+]i might be deleterious, we find it to
remain well below the predicted value in the nSR human atrial
cardiomyocyte model (∼360 nM).
In our previous study in nSR (Ellinwood et al., 2017), we
found that O & I inhibitors with the fastest drug-binding kinetics
(30–100 s−1) cause ERP prolongation at 3-Hz pacing and no
APD prolongation at 1-Hz pacing. These same inhibitors display
favorable fast pacing-rate selectivity in atrial cardiomyocytes
from cAF according to our simulations shown in Figures 5A,B.
However, if we are not as concerned with APD prolongation
in cAF conditions at 1-Hz pacing, then drugs with a kon rate
in the intermediate drug-binding range (3–30 s−1) would also
be efficacious and perhaps more efficacious since they cause a
positive inotropic effect at 1-Hz pacing (Figures 5C,E).
Effect of Relative State-Specific Drug
Binding
Because many IKur inhibitors bind to multiple states of KV1.5
with variable affinity (Bouchard and Fedida, 1995; Lagrutta et al.,
2006; Ford et al., 2016), we allowed kon for the open state
(kon,O), koff for the open state (koff,O), kon for the inactivated
state (kon,I), and koff for the inactivated state (koff,I) to have any
of the three binding rates (0.01, 3, and 100 s−1), and varied
them independently to yield 81 different drug combinations. We
studied the effects of these IKur blockers in cAF conditions using a
[drug] equal to their IC50 value at 1-Hz pacing for APD and 3-Hz
pacing for ERP. Then, we compared the outputs of APD and ERP
to no block, 50, and 100% reduction in GKur in cAF conditions
(Figure 6, dotted lines), along with no block in nSR conditions
(Figure 6, dashed lines).
Figures 6A,B display the relationship between APD (at 1-Hz
pacing) and KO/KI. Data points in Figure 6A are separated by
IC50 cutoffs of 0.1µM, 10µM, and 1mM, and show that when
KO/KI < 1, we almost always obtain maximal AP prolongation
(this also corresponds to larger IC50 values). In Figure 6B, we
separated the points according to the drug’s koff,O rate (0.01, 3, or
100 s−1), which revealed that when KO/KI > 1, we only obtain
significant AP prolongation when koff,O is equal to 3 s
−1 (i.e.,
the intermediate drug-binding rate). These results in the cAF-
remodeled atrial cardiomyocyte correspond well with the results
from our previous study of IKur inhibitors in nSR (Ellinwood
et al., 2017). Nevertheless, none of the 81 simulated O & I
inhibitors in Figure 6 prolong the AP beyond the APD found in
nSR at 1-Hz pacing.
Figures 6C,D present the relationship between APD at 1-
Hz pacing and ERP at 3-Hz pacing for the O & I inhibitors
with a variable KO/KI ratio. In Figure 6C, light gray symbols
correspond to KO/KI ≤ 1, and dark symbols correspond to
KO/KI > 1). The O & I blockers displaying favorable pacing-rate
selectivity, i.e., producing ERP prolongation at 3-Hz pacing while
having moderate effect on APD (and ERP) at 1-Hz pacing, are
the ones with KO/KI > 1, except if koff,O equals 3 s
−1. However,
as none of the 81 simulated O & I inhibitors in Figure 6 prolong
the APD beyond that found in nSR at 1-Hz pacing, one could
argue that none of the drugs is expected to cause harmful AP
prolongation when AF is terminated. To try and enrich our
metric, in Figure 6D we also categorize the drugs according to
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FIGURE 5 | Effect of drug-binding kinetics on APD90, ERP, CaTamp, and diastolic [Ca
2+]i for an open and inactivated state blocker. (A) APD90 (at 1Hz), (B) ERP (at
3Hz), (C,D) CaTamp (at 1 and 3Hz), and (E,F) diastolic [Ca
2+]i (at 1 and 3Hz) are plotted for open and inactivated state blockers with varying binding kinetics, which
were simulated via permutations of nine different drug-binding rates of (from 0.01 to 100 s−1) while keeping kon,O = kon,I and koff,O = koff,I. CaTamp is 103.6, 109.4,
and 120.4 nM at 1Hz, and 103.4, 120.4, and 135.9 nM at 3Hz for drug-free, 50 and 100% IKur block, respectively. Diastolic [Ca
2+]i is 157.6, 160.0, and 165.2 nM at
1Hz, and 253.3, 266.9, and 286.9 nM at 3Hz for drug-free, 50 and 100% IKur block, respectively.
percent increase in CaTamp. The best-performing drugs will cause
ERP prolongation at 3-Hz pacing in cAF (above nSR), and have
a positive inotropic effect (Figure 6D, black). Corresponding
with the results showcased in Figure 5, drugs with intermediate
binding rates (e.g., koff,O = 3 s
−1) may thus be favorable given
their stronger inotropic effect.
Frontiers in Pharmacology | www.frontiersin.org 8 November 2017 | Volume 8 | Article 799
Ellinwood et al. IKur Inhibitors in Chronic Atrial Fibrillation
FIGURE 6 | Effect of conformational state affinity and drug-binding kinetics of an open and inactivated state blocker on APD90, ERP, and Ca
2+ handling. Open and
inactivated state IKur blockers with varying affinities to the open and inactivated states were simulated via permutations of three different rates of binding kinetics (0.01,
3, and 100 s−1). Simulations were equilibrated for 300 beats at 1-Hz pacing or 900 beats at 3-Hz pacing using a [drug] equal to the IC50 value. (A,B) report APD90
values (at 1Hz) plotted as a function of the ratio of the open to the inactivated state affinity (KO/KI) used in each simulation. (C,D) report APD90 (at 1Hz) and ERP
values (at 3Hz). Color code in (A) is for IC50 levels. Symbols in (B,C,D) indicate various koff,O. Shades in (C) reflect either higher affinity to the open or the inactivated
state. Color code in (D) corresponds to the variable degree of CaTamp increase (at 1Hz) induced by IKur block. Horizontal and vertical lines represent APD90 and ERP
values obtained in cAF in drug-free conditions, and 50 and 100% reduction in GKur (dotted lines), and in nSR in drug-free conditions (dashed lines).
DISCUSSION
In this study, we sought to determine if IKur is a suitable anti-
AF target despite it being downregulated in cAF patients, and, if
so, what are the kinetic and state-dependent binding properties
that maximize anti-AF efficacy and limit potential cardiotoxicity.
Building off our previous study in nSR conditions (Ellinwood
et al., 2017), we implemented an in silico assessment of IKur
inhibitors in cAF atrial cardiomyocyte models, and identified
metrics for delineating ideal KV1.5 blockers against AF. Our
results point to IKur inhibition as a valid strategy to prolong atrial
refractoriness also generating a positive inotropic effect in cAF
conditions. Although increasing force generation may not be a
useful therapeutic goal at the high atrial rates seen during AF,
it can be important to counteract atrial hypocontractility after
cardioversion of AF to nSR. Interestingly, our simulations suggest
that electrophysiological properties in cAF cardiomyocytes, such
as shorter AP andmore depolarized plateau potential, bothmight
act to increase efficacy and dampen cardiotoxicity of potential
KV1.5-targeting drugs as compared to nSR (Ellinwood et al.,
2017; Figure 7).
IKur Role in APD and ERP Regulation Is
Preserved Despite Its Downregulation in
cAF
Figure S7 shows the differences in the time courses of Em, IKur,
and closed, open, and inactivated state occupancies of KV1.5
in cAF and nSR during the AP. Despite the reduced peak
current, the channel stays open later in cAF (at both 1- and 3-
Hz pacing) because of the more depolarized AP plateau. Thus,
the consequences of IKur inhibition, including the extent of AP
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FIGURE 7 | Summary of main findings. Atrial cardiomyocytes in cAF (solid lines) vs. nSR (dotted lines) have different AP trajectories, including a shorter APD and more
depolarized plateau (top left). The latter causes longer open state occupancy (right, blue solid vs. dashed lines) and stronger inactivation of the channel in cAF
conditions (especially at fast pacing rates, right, green solid vs. dashed lines). IKur inhibitors appear also more potent in cAF vs. nSR (bottom left). These factors render
APD and ERP more sensitive to inhibition by O and O & I inhibitors of KV1.5, thus increasing efficacy of these drugs in cAF vs. nSR. Because basal APD is shorter in
cAF, there are potentially less safety concerns due to drug-induced AP prolongation and subsequent afterdepolarization-driven proarrhythmia.
and ERP prolongation, depend not only on IKur magnitude (i.e.,
maximal conductance), but also on other fluxes affected by AF-
induced remodeling, which affect Em and thus Em-dependent
properties of IKur (Figure 7). For example, our group and others
have hypothesized that the extent of AP and ERP prolongation
due to IKur blockade depends on the AF-induced remodeling of
other K+ currents (Lagrutta et al., 2006; Morotti et al., 2016a;
Aguilar et al., 2017; Colman et al., 2017), and relative strengths of
ICaL and IKur (Wettwer et al., 2004; Grandi and Maleckar, 2016).
Our sensitivity analysis (Figure 1C and Figures S1–S6) revealed
that APD90 and ERP are more sensitive to changes in GKur at
fast vs. slow pacing rates. Aguilar et al. recently determined that
the relative contribution of IKur to AP repolarization increases
at higher frequencies because of reduced activation of the rapid
delayed-rectifier current IKr (Aguilar et al., 2017). Our results
concur with these findings, as our sensitivity analysis shows that
APD90 and ERP are less sensitive to changes in GKr at 3-Hz
pacing as compared to 1-Hz pacing in nSR conditions (Figures
S2, S3). Most importantly, we also found that GKur impacted
the duration of AP repolarization and refractoriness more in
cAF vs. nSR (even though this parameter was halved in the cAF
model) at 3-Hz, but not at 1-Hz pacing (i.e., fast pacing-rate
selectivity). This is a favorable drug property to avoid harmful AP
prolongation (which is also limited by the reduced basal APD)
if AF is terminated. Similar to Aguilar et al. (2017), our results
suggest that the APD- (and ERP)-prolonging effect of IKur block
is not affected by IKur downregulation.
Enhanced Efficacy and Safety of IKur
Inhibitors in cAF vs. nSR
We focused here on O and O & I blockers because we have
previously shown that these inhibitors display fast pacing-rate
selectivity in nSR (Ellinwood et al., 2017). This choice was also
supported by the increased occupancy of open and inactivated
states in cAF conditions (Figure 7). In our previous report in nSR
(Ellinwood et al., 2017), we found that when kon = koff (i) slow
drug-binding kinetics caused minimal APD changes and modest
ERP prolongation; (ii) intermediate drug-binding kinetics led to
substantial AP and ERP prolongation; and (iii) fast drug-binding
kinetics failed to produce substantial AP or ERP prolongation
at normal pacing rate, but increased the ERP at 3-Hz pacing.
While in cAF the overall biphasic relationship between APD/ERP
and drug-binding kinetics was maintained (see Figures 2–4),
notably, at 1-Hz pacing rate, even the maximal AP prolongation
induced by IKur inhibition in cAF is not sufficient to reach
the APD observed in nSR in drug-free conditions. This might
indicate that there are less safety concerns for KV1.5 block
in cAF patients. At 3-Hz pacing, ERP prolongation is at least
equivalent to that caused by a constant 50% reduction in GKur,
and, for intermediate and fast drug-binding kinetics, the ERP
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is equal to or greater than the one obtained in nSR in drug-
free conditions. These observations suggest that O and O & I
inhibitors have a broader range of efficacy in cAF vs. nSR. We
assessed whether closed state inhibitors, which displayed reverse-
rate dependence in terms of potency (Ellinwood et al., 2017), may
also be effective and safe anti-AF agents in cAF conditions (Figure
S8). We found that these blockers prolong ERP at 3-Hz pacing
(Figure S8G) while minimally prolonging the cAF AP at 1-Hz
pacing at the fastest drug-binding kinetics (≥30 s−1, Figure S8B).
However, they had a smaller maximal effect and kinetic range
for prolonging the ERP at 3-Hz pacing beyond nSR conditions
as compared to O and O & I blockers.
We enriched our metric for quantifying anti-AF efficacy
and safety of IKur inhibitors by also accounting for changes in
Ca2+-handling parameters, namely CaTamp and diastolic [Ca
2+]i
(Tsujimae et al., 2008; Cavero and Holzgrefe, 2014; Lancaster and
Sobie, 2016; Li et al., 2017), which provided additional detail to
refine the search for best-performing drugs. In identifying the
ideal drug characteristics, we looked for inhibitors that prolong
ERP (especially at fast pacing rates), limit APD prolongation
at slow pacing-rates, and improve atrial inotropy, i.e., increase
CaTamp. Increasing force generation might be a useful outcome
after cardioversion to nSR.
When KO = KI, the best-performing O & I inhibitors were
those with intermediate kon rates (3–30 s
−1), because they
prolonged ERP at 3-Hz pacing and increased CaTamp and
diastolic [Ca2+]i at 1-Hz pacing (Figure 5). These inhibitors also
prolonged the AP at 1-Hz pacing and increased CaTamp and
diastolic [Ca2+]i at 3-Hz pacing—thus potentially predisposing
to harmful AP prolongation and Ca2+ overload. However, we
note that such cardiotoxicity is unlikely considering the fact that
the maximum increases of APD and CaTamp still remain far
below the corresponding values obtained in nSR in drug-free
conditions. In our previous study, we highlighted that the best-
performing drugs in nSRwere theO& I inhibitors with the fastest
drug-binding kinetics (Ellinwood et al., 2017). While these drugs
are still efficacious at prolonging ERP at 3-Hz pacing in cAF, they
have limited effect on Ca2+ handling.
When KI and KO were varied, the relationships between APD
at 1-Hz pacing and affinity ratio (KO/KI) are similar to those in
nSR (Figures 6A,B; Ellinwood et al., 2017), except none of the 81
simulated O& I inhibitors prolonged the AP beyond the duration
found in nSR in drug-free condition. Likewise, the relationship
between APD at 1-Hz pacing and ERP at 3-Hz pacing is similar to
nSR (Figures 6C,D; Ellinwood et al., 2017), but none of the drugs
exhibit obvious toxicity. The same O & I inhibitors simulated in
cAF conditions were more effective at prolonging ERP at 3-Hz
pacing rates as compared to nSR conditions. Thus, on average,
the same inhibitors in Figure 6 exhibit less toxicity and greater
efficacy in cAF vs. nSR.
In their simulation study, Aguilar et al. concluded that the
ability of (simple pore) IKur block to terminate simulated AF was
greatly attenuated by remodeling, because the block-induced AP
prolongation was insufficient to counteract the strong effects of
cAF-induced remodeling (Aguilar et al., 2017). Notably, here we
show that depending on the drug-binding kinetics, certain IKur
inhibitors can markedly counteract the effect of cAF-associated
remodeling, and bring AP and ERP parameters close to nSR
values, i.e., have a greater effect than simple pore blockers.
Limitations and Future Directions
We presented a theoretical study of the effects of IKur inhibitors
in cAF, and compared our results to our previous study in
nSR atrial cardiomyocytes. We acknowledge several limitations
to the described approach, which provide opportunities for
further extensions. First, we only considered direct drug effects
on KV1.5, and future analysis should consider multi-channel
effects of IKur inhibitors (Ford and Milnes, 2008; Li et al.,
2017), as this realistically occurs in vivo in the clinical setting.
We only considered cardiotoxicity at the atrial level, assuming
that the absence of IKur in ventricles prevents ventricular
proarrhythmia. However, this might not be true for real IKur
blockers with off-target effects. Here, we simulated IKur block
at the cellular level with no contribution of structural tissue
remodeling and defined IKur inhibitors’ efficacy and toxicity by
tracking only electrophysiological properties such as APD, ERP,
CaTamp, and diastolic [Ca
2+]i. While this is an important first
step in defining metrics for AF-selectivity, other arrhythmia
indices and integration of such simulations into tissue and
organ level models would improve our ability to discern best-
performing drug characteristics of IKur inhibitors against AF.
Since many antiarrhythmic drugs lose anti-AF efficacy with
the progression of the arrhythmia, particularly in patients
with atrial cardiomyopathy and comorbidities (Goette et al.,
2016), IKur block might be less efficient against AF in the
structurally remodeled atrium. Further studies including 2- and
3-dimensional tissue simulations are needed to address this
clinically relevant issue. In addition, machine-learning methods
have begun to be implemented to analyze AP metrics after the
application of a drug and classify the risk (e.g., torsadogenic
risk) of the candidate drug (Lancaster and Sobie, 2016). Such
methods can also highlight which ion channels contribute most
to such risk. Furthermore, this study revealed that the efficacy
and toxicity of IKur inhibitors is modulated by the extent of
atrial ionic remodeling, and likely by the relative expressions
of many ion channels and transporters (Figures S1–S6). Thus,
given the differences in AP properties and ion channel expression
in patients with AF (Heijman et al., 2014), and differences
in IKur remodeling in the right vs. the left atria (Dobrev and
Ravens, 2003; Caballero et al., 2010), we hypothesize that certain
subpopulations of nSR and cAF patients may be more responsive
to therapy with IKur inhibitors, i.e., degree and heterogeneity of
IKur remodeling in atrial tissue might impact safety and anti-
AF efficacy of drugs. Future studies could identify which cell
characteristics lead to more favorable responses to anti-IKur
therapy utilizing sensitivity analysis and variations of nSR and
cAF models similar to the methods discussed in Figure 1 and
in (Sobie, 2009; Lee et al., 2013; Cummins et al., 2014; Devenyi
and Sobie, 2015; Morotti and Grandi, 2017). This information
could be useful for a personalized (precision) medicine approach
to AF treatment or helpful in suggesting potential combination
therapies with IKur inhibitors.
Finally, advancements in high-throughput screening methods
(Obergrussberger et al., 2016; Picones et al., 2016; Molokanova
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et al., 2017) provide functional drug screening capabilities that
can be coupled with in silico investigations such as the one
described here to help identify actual candidate compounds for
in vivo testing. Such technologies can potentially be implemented
to simultaneously screen many KV1.5-selective compounds for
the desired kinetics, state-dependence, and rate-dependence
of IKur block. In addition, multi-parallel recordings from
atrial-like cardiomyocytes from induced human pluripotent
stem cells is also emerging as a preclinical model for evaluating
drugs targeting atrial-specific ion channels, such as KV1.5
(Devalla et al., 2015), particularly in combination with AP-
clamp experiments. These could be coupled with in silico
studies such as this one for delineating the ideal properties
of AF-selective drugs and gaining a more comprehensive
understanding of the arrhythmic risk of candidate
compounds.
CONCLUSIONS
In this study, efficacy and cardiotoxicity on cAF atrial
cardiomyocytes of theoretical IKur inhibitors were assessed in
silico. We concluded that IKur is a promising anti-AF target,
even if strongly downregulated in cAF condition. We confirmed
that steady-state IC50 values are insufficient to predict how
candidate compounds will interact with a dynamically changing
electrophysiological substrate, thus emphasizing the importance
of accounting for kinetic and state-dependent drug-binding
properties. This approach could aid experimental and screening
efforts to identify the complex net impact of IKur inhibition in
different AF-remodeling conditions during the pre-clinical drug
development process.
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